Table 2.

Clinical symptoms at diagnosis of anti-IgLON5 disease in described patients.

	N (%)
Sleep disturbances	135 (83.3)
Sleep breathing problems	86/123 (69.9)
Stridor or vocalization during sleep	41/123 (33.3)
Abnormal sleep behaviors	72/123 (58.5)
Insomnia (sleep onset or fragementation)	62/123 (50.4)
excessive day sleepiness	52/123 (42.3)
Bulbar dysfunction	112 (69.1)
Dysphagia	88/111 (79.3)
Dysarthria	61/111 (55.0)
Episodes of acute respiratory failure or dyspnea	33/111 (29.7)
Stridor during wakefulness	14 /111(12.6)
Vocal cord palsy or laryngospasm	30/111 (27.0)
Movement disorder	126 (77.8)
Gait instability	94/125 (75.2)
Ataxia	45/125 (36.0)
Chorea	37/125 (29.6)
Parkinsonism	29/125 (23.2)
Dystonia	24/125 (19.2)
Abnormal body postures and rigidity	24/125 (19.2)
Tremor	24/125 (19.2)
Other hyperkinesias	41/125 (32.8)
Orofacial dyskinesia	1/41 (2.4)
Myoclonus	14/41 (34.1)
Akathisia	10/41 (24.4)
Myorhythmia	10/41 (24.4)
Myokymia	8/41 (19.5)
Abdominal dyskinesia	5/41 (12.2)
Dysautonomia	70 (43.2)
Urinary dysfunction (urgency and incontinence)	35/64 (54.7)
Spontaneous episodes of intense perspiration	23/64 (35.9)
Anhidrosis	3/64 (4.7)
Gastrointestinal problems (constipation, diarrhea)	11/64 (17.2)
Cardiac dysfuction	12/64 (18.8)
Orthostatic hypotension	6/64 (9.4)
Erectile dysfunction	2/64 (3.1)
Oculomotor abnormalities	73 (45.1)
Gaze palsies	39/73 (53.4)
Abnormal saccades	23/73 (31.5)
Abnormal pursuit	19/73 (26.0)
Nystagmus	26/73 (35.6)
Eyelid ptosis	18/73 (24.7)
Neuromuscular	21 (13.0)
Fasciculations in muscles	18/21 (85.7)
Muscle weakness/atrophy	8/21 (38.1)
Cognitive impairment	84 (51.9)
Dementia or memory impairment	45/62 (72.6)
Confusional episodes (delirium)	23/62 (37.1)
Other neuropsychiatric symptoms
Affective disorder	16/65 (24.6)
Depression	11/16 (68.8)
Anxiety	6/16 (37.5)
Hallucination	14/65 (21.5)
Executive dysfunction	5/65 (7.7)
Abnormal behavior	14/65 (21.5)
Visuospatial dysfunction	8/65 (12.3)
Seizure	11/102 (10.8)